Marplan® (isocarboxazid) Tablets Efficacy in Treatment-Resistant Depression*
In the United States an estimated 21 million people suffer from the symptoms of depression5. In many cases the symptoms last for only a short period of time and relief can be obtained from the commonly prescribed SSRI or SSNI classes of antidepressant drugs.
But, for some patients, symptoms simply do not seem to go away. And, although SSRI/SSNI drugs may offer some limited relief, symptoms continue to persist. That is a different kind of depression—the treatment-resistant* kind*.
If you have treatment-resistant depression*, you may require a different kind of antidepressant medication. That medication is Marplan® (isocarboxazid) Tablets—a drug utilizing MAO Inhibitor chemistry that – unlike other kinds of antidepressant medication—works to raise levels of all three of the key brain chemicals that elevate mood3.
Marplan® (isocarboxazid) Tablets' 'multi-transmitter' effect (raising the levels of the chemical messengers serotonin + norepinephrine + dopamine in the brain) represents a different approach that your doctor may employ to bring the resistant* symptoms of your depression under control3.
Analyses of clinical studies involving hundreds of patients show that Marplan® (isocarboxazid) Tablets therapy is effective in 60% to 69% of those treated7.
*Treatment failure with first-line antidepressants.
Please see Full Prescribing Information including BOXED WARNINGS regarding increased risk of suicidality in children and adolescents. MAO Inhibitors are contraindicated with certain drugs. Potential hypertensive crises may occur with foods that contain tyramine. As with all antidepressants, patients should be observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of treatment.
Suicidality and Antidepressant Drugs
Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies with Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of Marplan® (isocarboxazid) Tablets or any other antidepressant in a child, adolescent or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Marplan® (isocarboxazid) Tablets is not approved for use in pediatric patients. (See Warnings: Clinical Worsening and Suicide Risk, Precautions: Information for Patients, and Precautions: Pediatric Use).
Pooled analyses of short-term (4 to 16 weeks) placebo-controlled trials of 9 antidepressant drugs (SSRIs and others) in children and adolescents with major depressive disorder (MDD), obsessive compulsive disorder (OCD), or other psychiatric disorders (a total of 24 trials involving over 4400 patients) have revealed a greater risk of adverse events representing suicidal thinking or behavior (suicidality) during the first few months of treatment in those receiving antidepressants. The average risk of such events in patients receiving antidepressants was 4%, twice the placebo risk of 2%. No suicides occurred in these trials.